Viatris Archives -

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition

Merck defends blockbuster Januvia franchise from patent challenge

https://pharmaphorum.com/news/merck-defends-blockbuster-januvia-franchise-from-patent-challenge/

Viatris (formerly Mylan) has become the first drugmaker to win full FDA approval for a generic version of

Update: FDA clears first generic of AZ’s blockbuster Symbicort

https://pharmaphorum.com/news/fda-clears-first-generic-of-azs-blockbuster-symbicort/

India’s Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of

Biocon buys Viatris biosimilars for $3.3bn, eyes IPO

https://pharmaphorum.com/news/biocon-buys-viatris-biosimilars-for-3-3bn-eyes-ipo/

A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing

AstraZeneca breathes sigh of relief as court blocks US Symbicort generic

https://pharmaphorum.com/news/astrazeneca-breathes-sigh-of-relief-as-court-blocks-us-symbicort-generic/

Mylan’s $12 billion takeover of Pfizer’s Upjohn unit has been cleared by the US authorities, but on the

FTC clears Mylan merger with Pfizer’s Upjohn – with conditions

https://pharmaphorum.com/news/ftc-clears-mylan-merger-with-pfizers-upjohn-with-conditions/

Viatris